A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma.
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Adil Daud
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Adil Daud
Immune therapy and Clinical Trials
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Genentech, Inc.
- ID
- NCT03815058
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated